Gilead Sciences, Inc. (ETR: GIS)
Market Cap | 110.75B |
Revenue (ttm) | 25.37B |
Net Income (ttm) | 112.97M |
Shares Out | n/a |
EPS (ttm) | 0.09 |
PE Ratio | 980.35 |
Forward PE | n/a |
Dividend | 2.85 (3.21%) |
Ex-Dividend Date | Dec 13, 2024 |
Volume | 873 |
Open | 87.48 |
Previous Close | 87.68 |
Day's Range | 86.88 - 89.02 |
52-Week Range | 57.29 - 92.80 |
Beta | 0.20 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 3, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences Inc (GILD) to Present at J.P. Morgan Healthcare Conference
Gilead Sciences Inc (GILD) to Present at J.P. Morgan Healthcare Conference
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning ...
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...
(GILD) - Analyzing Gilead Sciences's Short Interest
Gilead Sciences's (NYSE: GILD) short percent of float has risen 29.66% since its last report. The company recently reported that it has 23.41 million shares sold short , which is 1.88% of all regular...
Gilead raises Assembly Bio stake to ~30%
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed addi...
Lightning Round: Uber is attractive at these levels, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Oracle, Gilead Sciences, Core Scientific, and Uber.
Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD)
Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD)
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Gilead, Terray to collaborate on small molecule drugs
Gilead Sciences (GILD) and Terray Therapeutics have entered into a strategic collaboration to discover and develop small molecule therapeutics. Read more here.
Gilead gets FDA breakthrough therapy status for Trodelvy
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (s...
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapie...
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to...
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc...
Gilead gets positive EU regulatory opinion for seladelpar
Gilead Sciences Inc (GILD) Receives Positive CHMP Opinion for Seladelpar in Treating Primary ...
Gilead Sciences Inc (GILD) Receives Positive CHMP Opinion for Seladelpar in Treating Primary Biliary Cholangitis
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending selad...
Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...
Gilead appoints Dietmar Berger as Chief Medical Officer
Gilead (GILD) has announced the appointment of Dietmar Berger to succeed Merdad Parsey as Chief Medical Officer, effective January 2, 2025. Most recently, Berger was the Chief Medical Office
Gilead Sciences Appoints New Chief Medical Officer to Strengthen Leadership in Virology and Oncology
Gilead Sciences Appoints New Chief Medical Officer to Strengthen Leadership in Virology and Oncology
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leader...
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will bec...
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ: GILD) revealed that it is developing a once-yearly injectable formulation for lenacapavir. The annual formulation is curr...